WASHINGTON, D.C., April 9, 2026 – The ERISA Industry Committee (ERIC) submitted public comments this week to Colorado lawmakers, pushing back against proposed legislation (HB26-1327) that would violate long held federal legislative and judicial precedent allowing employer benefits plans established under the Employee Retirement Income Security Act (ERISA) to design and administer uniform benefits that reflect the needs of their nationwide workforces.
Miscellaneous Archives:
ERISA Preemption Victory: ERIC Applauds Sixth Circuit Ruling Upholding ERISA Employer Plan Protections
WASHINGTON, D.C., April 8, 2026 –The U.S. Court of Appeals for the Sixth Circuit yesterday affirmed the decision of the lower court in McKee Foods Corporation v. BFP, Inc. The court agreed with McKee Foods that the Employee Retirement Income Security Act (ERISA) preempts key provisions of Tennessee’s law requiring that employers include “any willing pharmacy” in the networks maintained by the pharmacy benefit plans that employers sponsor for workers and their families, among other provisions.
ERIC On Weyerhaeuser Pension Risk Transfer Case: A “Meaningful Outcome”
WASHINGTON, D.C., April 2, 2026 – On Thursday, April 2, The ERISA Industry Committee (ERIC) applauded this week’s dismissal of Maneman v. Weyerhaeuser Company by the U.S. District Court for the Western District of Washington. The case represents a growing trend of class action litigation targeting pension plan transactions.
ERIC on Proposed Investment Rule: “A Meaningful and Important Step”
WASHINGTON, D.C., March 30, 2026 –The ERISA Industry Committee (ERIC) issued the following statement today regarding a new proposed rule from the Department of Labor (DOL) to clarify a fiduciary’s duty of prudence in selecting investment alternatives for retirement plans.
The ERISA Industry Committee Celebrates Its 50th Anniversary
WASHINGTON, D.C., March 25, 2026 – This week, The ERISA Industry Committee (ERIC) will mark its 50th anniversary during its annual spring conference in Washington, DC. While the conference will bring together large employer benefits, compensation, and legal professionals, along with federal policymakers for discussions on employee benefits, health care, and retirement policy, the event will also serve to commemorate a significant milestone in the organization’s history.
ERIC: RESTORE Act Will Drive Up Costs Without Improving Patient Care
Washington, D.C., March 19, 2026 – On Wednesday, the House Ways and Means Health Subcommittee held a hearing examining advances in kidney care, Medicare payment reforms for End Stage Renal Disease (ESRD), and the importance of health care solutions tailored to the needs of patients, including facilitating transplantation and home dialysis.
Employers Oppose Dialysis Policies that Increase Costs on Patients
WASHINGTON, DC – The Partnership for Employer-Sponsored Coverage (P4ESC) applauds Congress for raising the concerns of patients struggling with end-stage renal disease (ESRD) and opposes policies that would increase costs for these patients and the employers who provide their dialysis coverage such as the Restore Protections for Dialysis Patients Act.
ERIC Applauds Action on the ERISA Litigation Reform Act
Washington, D.C., March 17, 2026 – Today, Andy Banducci, Senior Vice President of Retirement and Compensation Policy at The ERISA Industry Committee (ERIC), issued the statement below following action by the U.S. House Education and Workforce Committee to advance the ERISA Litigation Reform Act (H.R. 6084).
Employer Coalition Applauds Bill to Boost Competition and Improve Affordability
Washington, D.C., March 16, 2026 – The ERISA Industry Committee (ERIC), along with a coalition of allies in the employer community, wrote to lawmakers today praising the introduction of the bipartisan “Healthy Competition for Better Care Act.”
ERIC Applauds FDA Action on Biosimilars to Reduce Drug Costs
Washington, D.C., March 10, 2026 – The ERISA Industry Committee (ERIC) issued the following statement today regarding the Trump Administration’s announcement to make biosimilar development faster and more affordable. The statement can be attributed to ERIC President and CEO, James Gelfand.